European School of Oncology (ESO)
Via Del Bollo 4
20123 - Milan, Italy
Programme and Organisation
Daniela Mengato - email@example.com - Tel : Tel: +39 02 8546 4523
Roberta Ventura - firstname.lastname@example.org - Tel : +39 02 85464532
Laura Richetti - ESO Bellinzona Office - email@example.com - Fax: +41 91 820 0953
EVALUATION QUESTIONNAIRE AND CERTIFICATES OF ATTENDANCE
Admitted participants and faculty members will be given access to an event-dedicated website where faculty’s CV, abstracts, presentations and course programme will be posted. On the website participants will also be able to insert their course evaluation and retrieve the certificates of attendance by e-mail.
The official language of the course will be English. No simultaneous translation will be provided.
The badge is the only official evidence of registration and should be worn at all times during the course. Loss of badge means loss of registration.
The organisers bear no responsibility for untoward events in connection with, before, during and after the course. Participants are strongly advised to take out their own personal and travel insurance coverage.
A limited number of travel grants will be available. Requests for support should be submitted together with the application form by the application deadline. Travel grant will be awarded up to Euro 300,00.
CME ACCREDITATION AND CERTIFICATES
Participants will be issued a certificate of attendance.
Application for CME recognition has been submitted to ESMO for ESMO-MORA accreditation, to the Accreditation Council of Oncology in Europe (ACOE) and to the European Accreditation Council for Continuing Medical Education (EACCME), an institution of the European Union of Medical Specialists (UEMS). The event was granted 9 European CME credits (ECMEC) by the European Accreditation Council for Continuing Medical Education (EACCME).
EACCME credits are recognized by the American Medical Association towards the Physician’s Recognition Award (PRA). EACCME certificate will be recognised by the Irish Postgraduate Training Bodies and Irish participants will be entitled to record these credits for purposes of Continuing Professional Development (CDP).
Grand Hotel Principe di Piemonte, Piazza Puccini, Viareggio, Italy (website: www.principedipiemonte.com)
Viareggio is located on the Tuscan coast. The main airports to reach Viareggio are Pisa (20 km) and Florence (80km), both of which have regular national and international flight connections.
SHARING PROGRESS IN CANCER CARE (SPCC)
Sharing Progress in Cancer Care programme (SPCC) is a pioneering partnership between the European School of Oncology (ESO) and some of the world’s leading pharmaceutical companies.
This course is organized through an unrestricted grant provided by Genomic Health, sustaining member of the SPCC programme.
FACULTY (as of November)
M.S. Aapro, IMO Clinique de Genolier, CH
F. André, Institut Gustave Roussy, Villejuif, FR
P.F. Conte, University Hospital, Modena, IT
F. Demichelis, Centre for Integrative Biology, University of Trento, IT
A. Di Leo, Ospedale "Misericordia e Dolce", Prato, IT
W. Gatzemeier, Istituto Clinico Humanitas, Milano, IT
R. Geva, Tel-Aviv Sourasky Medical Center, IL
J. Gligorov, Hopitaux Universitaires Paris Est Tenon, Paris, FR
J. Hugosson, Institute of Clinical Sciences, University of Gothenburg, SE
B. Kaufman, Sheba Medical Center, Tel Hashomer, IL
R. Labianca, Ospedali Riuniti di Bergamo, IT
L. Lacroix, Institut Gustave Roussy, Villejuif, FR
F. Penault-Llorca, Centre Anticancéreux Jean Perrin, Clermont-Ferrand, FR
R. Pirker, Medical University of Vienna, AT
P. Romero, Centre Anticancéreux Jean Perrin, Clermont-Ferrand, FR
R. Rouzier, Université Paris 6 Pierre et Hôpital Tenon, Paris, FR
H. Rugo, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, US
R. Valdagni, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, IT
WHERE DO WE STAND IN LUNG CANCER?
Treatment of advanced NSCLC: which drugs for which histology? And is histology reliable?
|Do we know how to chose the best maintenance treatment?|
R. Pirker, FR
New markers to define NSCLC and the potential of genomics
WHERE DO WE STAND IN COLORECTAL CANCER?
What to ask your pathologist? When do you need to know about microsatellite stability? Which k-ras mutation is important? What about b-raf?
|Where are we with genomic testing in CRC? When should we use it? |
R. Geva, IL
Metastatic CRC: when to use single agent, combination and agents working on EGFR inhibition and angiogenesis inhibition?
WHERE DO WE STAND IN PROSTATE CANCER?
|Basics of prostate cancer: screen shows cancer, but which patient needs intervention|
J. Hugosson, SE
|Prostate Cancer: Predictive Models for Decision Making|
R. Valdagni, IT
|Genomic tools in prostate cancer|
F. Demichelis, IT
WHERE DO WE STAND IN BREAST CANCER (Part 1)
|Prognosis modelling: nomogramms and/or molecular biology |
R. Rouzier, FR
|Triple-negative disease: no, not so simple! Can have an excellent prognosis…|
F. Penault-Llorca, FR
|Triple-negative disease relapses after adjuvant chemo: what do you do? Which research is going on? |
A. Di Leo, IT
|(Neo)-Adjuvant therapy of breast cancer in specific populations: which ones? Using which pathology tools to define these populations?|
P.F. Conte, IT
|Classic pathology: why is proliferation difficult to determine? Why is Ki-67 not a standard?|
P. Romero, IT
WHERE DO WE STAND IN BREAST CANCER (Part 2)
|Should we stop looking for microscopic disease in the lymph nodes?|
W. Gatzemeier, IT
|Genomic evaluation of breast cancer: what are the data?|
F. André, FR
Next generation sequencing genomic signatures
Do genomic tools impact daily practice in breast cancer treatment?
|Endocrine-resistance: genomic tools or simply use drugs like fulvestrant or everolimus? |
B. Kaufman, IL
|Current research in the development of biomarkers for HER-2 biology |
P.F. Conte, IT